Introduction：Basic information about CAS 179463-17-3|Cancidas, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Cancidas |
|---|
| CAS Number | 179463-17-3 | Molecular Weight | 1093.31000 |
|---|
| Density | / | Boiling Point | 1408.1ºC at 760 mmHg |
|---|
| Molecular Formula | C56H96N10O19 | Melting Point | / |
|---|
| MSDS | ChineseUSA | Flash Point | / |
|---|
Names
| Name | caspofungin acetate |
|---|
| Synonym | More Synonyms |
|---|
Cancidas BiologicalActivity
| Description | Caspofungin (Acetate) is an antifungal drug, and noncompetitively inhibits 1,3-β-d glucan synthase activity. |
|---|
| Related Catalog | Signaling Pathways >>Anti-infection >>FungalResearch Areas >>Infection |
|---|
| In Vivo | Mice injected with caspofungin at vitreal concentrations from 0.41 to 4.1 μM do not have significant alterations in their ERG waveforms, and their retinas have no detectable morphologic changes or loss of cells. At the vitreal concentration of 41 μM, caspofungin reduces the amplitudes of the a-waves, b-waves, and scotopic threshold responses of the ERG and also produces a decrease in the number of cells in the ganglion cell layer[1]. Caspofungin (8 mg/kg) or amphotericin B at 1 mg/kg given i.p. once daily for 7 days beginning at 30 h after infection resulted in 100% survival through day 28 relative to vehicle control treatment, which results in 100% mortality by day 11 after infectious challenge. Caspofungin reduces recovery of viable Candida from kidney and brain tissues compared to vehicle control treatment on day 5, when control burden peaked. Caspofungin-treated mice dosed with 2 mg/kg or greater have significantly lower brain burden than amphotericin-B-treated mice at day 5. Amphotericin B and caspofungin treatment reduce kidney fungal burden by 1.7 log CFU/g and 2.46 to 3.64 log CFU/g, respectively[2]. |
|---|
| Animal Admin | Antifungal therapy is initiated at 30 h after infectious challenge and is given by intraperitoneal (i.p.) injection once daily for 7 days. Mice are treated with caspofungin at 1, 2, 4, or 8 mg/kg/day, amphotericin B at 1 mg/kg/day, or vehicle control (sterile distilled water). Efficacy in this model is assessed in 3 ways: by monitoring survival in a group of 10 animals in each treatment group, by monitoring Candida burden in kidney and brain tissues in a second set of treated animals, and by histologically evaluating the kidneys and brains in a third set of treated animals. Mice are euthanized by CO2 inhalation, and tissues for both culture and histology are sampled at 30 h (vehicle-treated control only) and at days 5 (24 h after 4th dose), 8 (24 h after last dose), 14, 21 (caspofungin-treated only), and 28 after challenge. |
|---|
| References | [1]. Mojumder DK, et al. Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye. Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5796-803. [2]. Flattery, Amy M. et al. Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. Antimicrobial Agents and Chemotherapy (2011), 55(7), 3491-3497. |
|---|
Chemical & Physical Properties
| Boiling Point | 1408.1ºC at 760 mmHg |
|---|
| Molecular Formula | C56H96N10O19 |
|---|
| Molecular Weight | 1093.31000 |
|---|
| Exact Mass | 1092.64000 |
|---|
| PSA | 412.03000 |
|---|
| LogP | 0.06150 |
|---|
| Appearance of Characters | white to beige |
|---|
| Vapour Pressure | 0mmHg at 25°C |
|---|
| InChIKey | OGUJBRYAAJYXQP-AVOYSFSSSA-N |
|---|
| SMILES | CC(=O)O.CC(=O)O.CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(O)C(NCCN)NC(=O)C2C(O)CCN2C(=O)C(C(O)CCN)NC(=O)C(C(O)C(O)c2ccc(O)cc2)NC(=O)C2CC(O)CN2C(=O)C(C(C)O)NC1=O |
|---|
| Storage condition | ?20°C |
|---|
| Water Solubility | H2O: soluble15mg/mL (clear solution) |
|---|
Safety Information
| RIDADR | NONH for all modes of transport |
|---|
| RTECS | TP8046500 |
|---|
| HS Code | 2933990090 |
|---|
Customs
| HS Code | 2933990090 |
|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|---|
Articles1
More Articles
| Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model. Antimicrob. Agents Chemother. 51(6) , 2053-64, (2007) Triple antifungal combinations are used against refractory invasive aspergillosis without an adequate understanding of their pharmacodynamic interactions. We initially studied the in vitro triple comb... | |
Synonyms
| Mk0991 |
| L-743,872 |
| CASPOFUNGIN |
| Cancidas |
| Tetradecanamide, N-[(2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-12-[(2-aminoethyl)amino]-20-[(1R)-3-amino-1-hydroxypropyl]-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]tetracosahydro-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxo-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacycloheneicosin-9-yl]-10,12-dimethyl-, acetate (1:2) (salt) |
| N-{(2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-12-[(2-Aminoethyl)amino]-20-[(1R)-3-amino-1-hydroxypropyl]-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide acetate (1:2) |
| Caspofungin Diacetate |
| Caspofungin (Acetate) |
